NasdaqGM - Delayed Quote USD

Chimerix, Inc. (CMRX)

0.9253 +0.0114 (+1.25%)
At close: April 23 at 4:00 PM EDT
0.9450 +0.02 (+2.13%)
After hours: April 23 at 6:56 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
324.0000
324.0000
33,824.0000
1,979.0000
5,372.0000
Cost of Revenue
--
--
447.0000
--
--
Gross Profit
324.0000
324.0000
33,377.0000
1,979.0000
5,372.0000
Operating Expense
93,389.0000
93,389.0000
93,763.0000
92,489.0000
49,888.0000
Operating Income
-93,065.0000
-93,065.0000
-60,386.0000
-90,510.0000
-44,516.0000
Net Non Operating Interest Income Expense
10,970.0000
10,970.0000
2,919.0000
164.0000
994.0000
Other Income Expense
--
--
229,670.0000
-82,890.0000
--
Pretax Income
-82,095.0000
-82,095.0000
172,203.0000
-173,236.0000
-43,522.0000
Tax Provision
--
--
36.0000
--
--
Net Income Common Stockholders
-82,095.0000
-82,095.0000
172,167.0000
-173,236.0000
-43,522.0000
Diluted NI Available to Com Stockholders
-82,095.0000
-82,095.0000
172,167.0000
-173,236.0000
-43,522.0000
Basic EPS
-0.93
-0.93
1.97
-2.04
-0.70
Diluted EPS
-0.93
-0.93
1.94
-2.04
-0.70
Basic Average Shares
88,604.0260
88,604.0260
87,555.1100
84,930.2550
62,183.9470
Diluted Average Shares
88,604.0260
88,604.0260
88,776.1470
84,930.2550
62,183.9470
Total Operating Income as Reported
-93,065.0000
-93,065.0000
-60,386.0000
-173,400.0000
-44,516.0000
Total Expenses
93,389.0000
93,389.0000
94,210.0000
92,489.0000
49,888.0000
Net Income from Continuing & Discontinued Operation
-82,095.0000
-82,095.0000
172,167.0000
-173,236.0000
-43,522.0000
Normalized Income
-82,095.0000
-82,095.0000
-57,454.9862
-90,346.0000
-43,522.0000
Interest Income
10,970.0000
10,970.0000
2,919.0000
164.0000
994.0000
Net Interest Income
10,970.0000
10,970.0000
2,919.0000
164.0000
994.0000
EBIT
-93,065.0000
-93,065.0000
-60,386.0000
-90,510.0000
-44,516.0000
EBITDA
-92,974.0000
-92,974.0000
-60,288.0000
-90,343.0000
-44,114.0000
Reconciled Cost of Revenue
--
--
447.0000
--
--
Reconciled Depreciation
91.0000
91.0000
98.0000
167.0000
402.0000
Net Income from Continuing Operation Net Minority Interest
-82,095.0000
-82,095.0000
172,167.0000
-173,236.0000
-43,522.0000
Total Unusual Items Excluding Goodwill
--
--
229,670.0000
-82,890.0000
--
Total Unusual Items
--
--
229,670.0000
-82,890.0000
--
Normalized EBITDA
-92,974.0000
-92,974.0000
-289,958.0000
-7,453.0000
-44,114.0000
Tax Rate for Calcs
--
--
0.0000
--
--
Tax Effect of Unusual Items
--
--
48.0138
--
--
12/31/2020 - 4/11/2013

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

KZR Kezar Life Sciences, Inc.
0.8260
+0.49%
 
CTMX CytomX Therapeutics, Inc.
1.6800
+0.60%
 
ALGS Aligos Therapeutics, Inc.
0.8236
+2.82%
 
GOSS Gossamer Bio, Inc.
0.7376
-0.73%
 
SPRB Spruce Biosciences, Inc.
0.7012
+1.33%
 
ACET Adicet Bio, Inc.
2.1000
+5.00%
 
ACHL Achilles Therapeutics plc
0.7811
-2.24%
 
BCAB BioAtla, Inc.
2.2400
+2.75%
 
NKTR Nektar Therapeutics
1.4200
+4.41%
 
LIFE aTyr Pharma, Inc.
1.6200
-1.22%